{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:33:09Z","timestamp":1793435589766,"version":"4.5.0"},"reference-count":265,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-026-00722-w","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:01:09Z","timestamp":1783580469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Thalassaemia"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-7728","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric B.","family":"Piel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"de Montalembert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H. M.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali T.","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-903X","authenticated-orcid":false,"given":"Khaled M.","family":"Musallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Treadwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthat","family":"Fucharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Angastiniotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3579-8705","authenticated-orcid":false,"given":"Douglas","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Vichinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"De Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"722_CR1","doi-asserted-by":"crossref","unstructured":"Weatherall D. J. & Clegg J. B. The Thalassaemia Syndromes (Blackwell Science, 2001).","DOI":"10.1002\/9780470696705"},{"key":"722_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato, G. J. et al. Sickle cell disease. Nat. Rev. Dis. Primers 4, 18010 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"722_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2471\/BLT.06.036673","volume":"86","author":"B Modell","year":"2008","unstructured":"Modell, B. & Darlison, M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull. World Health Organ. 86, 480\u2013487 (2008).","journal-title":"Bull. World Health Organ."},{"key":"722_CR4","first-page":"704","volume":"79","author":"DJ Weatherall","year":"2001","unstructured":"Weatherall, D. J. & Clegg, J. B. Inherited haemoglobin disorders: an increasing global health problem. Bull. World Health Organ. 79, 704\u2013712 (2001).","journal-title":"Bull. World Health Organ."},{"key":"722_CR5","unstructured":"Huisman T. H. J., Carver M. F. H. & Baysal E. A Syllabus of Thalassemia Mutations (The Sickle Cell Anemia Foundation, 1997)."},{"key":"722_CR6","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood.V89.5.1762","volume":"89","author":"SL Schrier","year":"1997","unstructured":"Schrier, S. L. et al. The unusual pathobiology of hemoglobin constant spring red blood cells. Blood 89, 1762\u20131769 (1997).","journal-title":"Blood"},{"key":"722_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/asheducation-2009.1.26","volume":"2009","author":"S Fucharoen","year":"2009","unstructured":"Fucharoen, S. & Viprakasit, V. Hb H disease: clinical course and disease modifiers. Hematology 2009, 26\u201334 (2009).","journal-title":"Hematology"},{"key":"722_CR8","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMra1404415","volume":"371","author":"FB Piel","year":"2014","unstructured":"Piel, F. B. & Weatherall, D. J. The \u03b1-thalassemias. N. Engl. J. Med. 371, 1908\u20131916 (2014).","journal-title":"N. Engl. J. Med."},{"key":"722_CR9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00439-021-02361-5","volume":"140","author":"NY Leon","year":"2021","unstructured":"Leon, N. Y. & Harley, V. R. ATR-X syndrome: genetics, clinical spectrum, and management. Hum. Genet. 140, 1625\u20131634 (2021).","journal-title":"Hum. Genet."},{"key":"722_CR10","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood.V91.7.2213","volume":"91","author":"DHK Chui","year":"1998","unstructured":"Chui, D. H. K. & Waye, J. S. Hydrops fetalis caused by \u03b1-thalassemia: an emerging health care problem. Blood 91, 2213\u20132222 (1998).","journal-title":"Blood"},{"key":"722_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood-2016-08-697110","volume":"129","author":"D Songdej","year":"2017","unstructured":"Songdej, D., Babbs, C. & Higgs, D. R. An international registry of survivors with Hb Bart\u2019s hydrops fetalis syndrome. Blood 129, 1251\u20131259 (2017).","journal-title":"Blood"},{"key":"722_CR12","doi-asserted-by":"publisher","first-page":"D1063","DOI":"10.1093\/nar\/gkt911","volume":"42","author":"B Giardine","year":"2014","unstructured":"Giardine, B. et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 42, D1063\u2013D1069 (2014).","journal-title":"Nucleic Acids Res."},{"key":"722_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2021838","volume":"384","author":"AT Taher","year":"2021","unstructured":"Taher, A. T., Musallam, K. M. & Cappellini, M. D. \u03b2-Thalassemias. N. Engl. J. Med. 384, 727\u2013743 (2021).","journal-title":"N. Engl. J. Med."},{"key":"722_CR14","doi-asserted-by":"publisher","first-page":"a011700","DOI":"10.1101\/cshperspect.a011700","volume":"3","author":"SL Thein","year":"2013","unstructured":"Thein, S. L. The molecular basis of \u03b2-thalassemia. Cold Spring Harb. Perspect. Med. 3, a011700 (2013).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"722_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ijlh.13885","volume":"44","author":"CL Harteveld","year":"2022","unstructured":"Harteveld, C. L. et al. The hemoglobinopathies, molecular disease mechanisms and diagnostics. Int. J. Lab. Hematol. 44, 28\u201336 (2022).","journal-title":"Int. J. Lab. Hematol."},{"key":"722_CR16","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/ajh.27386","volume":"99","author":"A Achour","year":"2024","unstructured":"Achour, A. et al. Moderate\u2013severe beta-thalassemia intermedia phenotype caused by sextuplicated alpha-globin gene allele in two beta-thalassemia carriers. Am. J. Hematol. 99, 1655\u20131658 (2024).","journal-title":"Am. J. Hematol."},{"key":"722_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1532-429X-10-42","volume":"10","author":"B Modell","year":"2008","unstructured":"Modell, B. et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 10, 42 (2008).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"722_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000732","volume":"6","author":"D Farmakis","year":"2022","unstructured":"Farmakis, D. et al. 2021 Thalassaemia International Federation guidelines for the management of transfusion-dependent thalassemia. HemaSphere 6, e732 (2022).","journal-title":"HemaSphere"},{"key":"722_CR19","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1002\/ajh.26056","volume":"96","author":"KM Musallam","year":"2021","unstructured":"Musallam, K. M. et al. Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later. Am. J. Hematol. 96, E54\u2013E56 (2021).","journal-title":"Am. J. Hematol."},{"key":"722_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ajh.27194","volume":"99","author":"KM Musallam","year":"2024","unstructured":"Musallam, K. M. et al. \u2018Phenoconversion\u2019 in adult patients with \u03b2-thalassemia. Am. J. Hematol. 99, 490\u2013493 (2024).","journal-title":"Am. J. Hematol."},{"key":"722_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/321744a0","volume":"321","author":"J Flint","year":"1986","unstructured":"Flint, J. et al. High frequencies of \u03b1-thalassaemia are the result of natural selection by malaria. Nature 321, 744\u2013750 (1986).","journal-title":"Nature"},{"key":"722_CR22","doi-asserted-by":"publisher","first-page":"a011692","DOI":"10.1101\/cshperspect.a011692","volume":"2","author":"TN Williams","year":"2012","unstructured":"Williams, T. N. & Weatherall, D. J. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb. Perspect. Med. 2, a011692 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"722_CR23","first-page":"390","volume":"48","author":"G Modiano","year":"1991","unstructured":"Modiano, G. et al. Protection against malaria morbidity: near-fixation of the \u03b1-thalassemia gene in a Nepalese population. Am. J. Hum. Genet. 48, 390\u2013397 (1991).","journal-title":"Am. J. Hum. Genet."},{"key":"722_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ejh.13512","volume":"105","author":"A Kattamis","year":"2020","unstructured":"Kattamis, A., Forni, G. L., Aydinok, Y. & Viprakasit, V. Changing patterns in the epidemiology of \u03b2-thalassemia. Eur. J. Haematol. 105, 692\u2013703 (2020).","journal-title":"Eur. J. Haematol."},{"key":"722_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/bmj.317.7161.761","volume":"317","author":"PS Gill","year":"1998","unstructured":"Gill, P. S. & Modell, B. Thalassaemia in Britain: a tale of two communities. Births are rising among British Asians falling in Cypriots. BMJ 317, 761\u2013762 (1998).","journal-title":"BMJ"},{"key":"722_CR26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3109\/07853890.2015.1091942","volume":"47","author":"FA Sayani","year":"2015","unstructured":"Sayani, F. A. & Kwiatkowski, J. L. Increasing prevalence of thalassemia in America: implications for primary care. Ann. Med. 47, 592\u2013604 (2015).","journal-title":"Ann. Med."},{"key":"722_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11831-4","volume":"21","author":"JZ Xu","year":"2021","unstructured":"Xu, J. Z. et al. Identification of optimal thalassemia screening strategies for migrant populations in Thailand using a qualitative approach. BMC Public Health 21, 1796 (2021).","journal-title":"BMC Public Health"},{"key":"722_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-97","volume":"9","author":"PA Martinez","year":"2014","unstructured":"Martinez, P. A. et al. Haemoglobinopathies in Europe: health & migration policy perspectives. Orphanet J. Rare Dis. 9, 97 (2014).","journal-title":"Orphanet J. Rare Dis."},{"key":"722_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/03630269.2022.2025824","volume":"46","author":"K Paiboonsukwong","year":"2022","unstructured":"Paiboonsukwong, K., Yupin, J., Pranee, W. & Fucharoen, S. Thalassemia in Thailand. Hemoglobin 46, 53\u201357 (2022).","journal-title":"Hemoglobin"},{"key":"722_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/thalassrep13040022","volume":"13","author":"L Rujito","year":"2023","unstructured":"Rujito, L., Maritska, Z. & Sofro, A. S. \u03b2 Thalassemia mutation flow in Indonesia: a migration perspective. Thalass. Rep. 13, 253\u2013261 (2023).","journal-title":"Thalass. Rep."},{"key":"722_CR31","doi-asserted-by":"publisher","first-page":"7474","DOI":"10.4081\/thal.2018.7474","volume":"8","author":"J Old","year":"2018","unstructured":"Old, J. et al. New challenges in diagnosis of haemoglobinopathies: migration of populations. Thalass. Rep. 8, 7474 (2018).","journal-title":"Thalass. Rep."},{"key":"722_CR32","doi-asserted-by":"publisher","first-page":"102619","DOI":"10.1016\/j.eclinm.2024.102619","volume":"72","author":"Y Tuo","year":"2024","unstructured":"Tuo, Y. et al. Global, regional, and national burden of thalassemia, 1990\u20132021: a systematic analysis for the Global Burden of Disease study 2021. eClinicalMedicine 72, 102619 (2024).","journal-title":"eClinicalMedicine"},{"key":"722_CR33","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.1016\/S2352-3026(25)00286-8","volume":"12","author":"B Gianesin","year":"2025","unstructured":"Gianesin, B. et al. Incorporating national disease burden in GBD estimates of haemoglobinopathies in Italy. Lancet Haematol. 12, e857\u2013e859 (2025).","journal-title":"Lancet Haematol."},{"key":"722_CR34","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/ajh.27006","volume":"98","author":"KM Musallam","year":"2023","unstructured":"Musallam, K. M. et al. Epidemiology of clinically significant forms of alpha- and beta-thalassemia: a global map of evidence and gaps. Am. J. Hematol. 98, 1436\u20131451 (2023).","journal-title":"Am. J. Hematol."},{"key":"722_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(81)91682-2","volume":"317","author":"MA Angastiniotis","year":"1981","unstructured":"Angastiniotis, M. A. & Hadjiminas, M. G. Prevention of thalassaemia in Cyprus. Lancet 317, 369\u2013371 (1981).","journal-title":"Lancet"},{"key":"722_CR36","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/bmj.329.7475.1134","volume":"329","author":"A Samavat","year":"2004","unstructured":"Samavat, A. & Modell, B. Iranian national thalassaemia screening programme. BMJ 329, 1134\u20131137 (2004).","journal-title":"BMJ"},{"key":"722_CR37","unstructured":"Thalassaemia International Federation. Global Thalassaemia Review 2025 https:\/\/thalassaemia.org.cy\/what-we-do\/global-thalassaemia-review\/ (2026)."},{"key":"722_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/ijns7020030","volume":"7","author":"CD Padilla","year":"2021","unstructured":"Padilla, C. D. et al. Successful implementation of newborn screening for hemoglobin disorders in the Philippines. Int. J. Neonatal Screen. 7, 30 (2021).","journal-title":"Int. J. Neonatal Screen."},{"key":"722_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1586\/ehm.09.74","volume":"3","author":"R Colah","year":"2010","unstructured":"Colah, R., Gorakshakar, A. & Nadkarni, A. Global burden, distribution and prevention of \u03b2-thalassemias and hemoglobin E disorders. Expert Rev. Hematol. 3, 103\u2013117 (2010).","journal-title":"Expert Rev. Hematol."},{"key":"722_CR40","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3324\/haematol.2024.286886","volume":"110","author":"B Gianesin","year":"2025","unstructured":"Gianesin, B. et al. Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study. Haematologica 110, 1211\u20131216 (2025).","journal-title":"Haematologica"},{"key":"722_CR41","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.3324\/haematol.2021.278684","volume":"106","author":"KM Musallam","year":"2021","unstructured":"Musallam, K. M. et al. Survival and causes of death in 2,033 patients with non-transfusion-dependent \u03b2-thalassemia. Haematologica 106, 2489\u20132492 (2021).","journal-title":"Haematologica"},{"key":"722_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.110.2865.543","volume":"110","author":"L Pauling","year":"1949","unstructured":"Pauling, L., Itano, H. A., Singer, S. J. & Wells, I. C. Sickle cell anemia, a molecular disease. Science 110, 543\u2013548 (1949).","journal-title":"Science"},{"key":"722_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrg1406","volume":"5","author":"DJ Weatherall","year":"2004","unstructured":"Weatherall, D. J. Thalassaemia: the long road from bedside to genome. Nat. Rev. Genet. 5, 625\u2013631 (2004).","journal-title":"Nat. Rev. Genet."},{"key":"722_CR44","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bjh.13938","volume":"173","author":"SK Nandakumar","year":"2016","unstructured":"Nandakumar, S. K., Ulirsch, J. C. & Sankaran, V. G. Advances in understanding erythropoiesis: evolving perspectives. Br. J. Haematol. 173, 206\u2013218 (2016).","journal-title":"Br. J. Haematol."},{"key":"722_CR45","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nsmb.2784","volume":"21","author":"E Smith","year":"2014","unstructured":"Smith, E. & Shilatifard, A. Enhancer biology and enhanceropathies. Nat. Struct. Mol. Biol. 21, 210\u2013219 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"722_CR46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/0092-8674(95)90287-2","volume":"80","author":"RJ Gibbons","year":"1995","unstructured":"Gibbons, R. J., Picketts, D. J., Villard, L. & Higgs, D. R. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell 80, 837\u2013845 (1995).","journal-title":"Cell"},{"key":"722_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-13","volume":"5","author":"CL Harteveld","year":"2010","unstructured":"Harteveld, C. L. & Higgs, D. R. \u03b1-Thalassaemia. Orphanet J. Rare Dis. 5, 13 (2010).","journal-title":"Orphanet J. Rare Dis."},{"key":"722_CR48","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1182\/blood-2015-03-633594","volume":"125","author":"S Mettananda","year":"2015","unstructured":"Mettananda, S., Gibbons, R. J. & Higgs, D. R. \u03b1-Globin as a molecular target in the treatment of \u03b2-thalassemia. Blood 125, 3694\u20133701 (2015).","journal-title":"Blood"},{"key":"722_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2141.2004.05257.x","volume":"128","author":"M-l Cheng","year":"2005","unstructured":"Cheng, M.-l. et al. Antioxidant deficit and enhanced susceptibility to oxidative damage in individuals with different forms of \u03b1-thalassaemia. Br. J. Haematol. 128, 119\u2013127 (2005).","journal-title":"Br. J. Haematol."},{"key":"722_CR50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40291-018-0373-5","volume":"23","author":"E Fibach","year":"2019","unstructured":"Fibach, E. & Dana, M. Oxidative stress in \u03b2-thalassemia. Mol. Diagn. Ther. 23, 245\u2013261 (2019).","journal-title":"Mol. Diagn. Ther."},{"key":"722_CR51","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ajh.27500","volume":"100","author":"R Bou-Fakhredin","year":"2025","unstructured":"Bou-Fakhredin, R., Cappellini, M. D., Taher, A. T. & De Franceschi, L. Hypercoagulability in hemoglobinopathies: decoding the thrombotic threat. Am. J. Hematol. 100, 103\u2013115 (2025).","journal-title":"Am. J. Hematol."},{"key":"722_CR52","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.68217","volume":"10","author":"M Castro-Mollo","year":"2021","unstructured":"Castro-Mollo, M. et al. The hepcidin regulator erythroferrone is a new member of the erythropoiesis-iron-bone circuitry. eLife 10, e68217 (2021).","journal-title":"eLife"},{"key":"722_CR53","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/bjh.13820","volume":"172","author":"C Camaschella","year":"2016","unstructured":"Camaschella, C. & Nai, A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br. J. Haematol. 172, 512\u2013523 (2016).","journal-title":"Br. J. Haematol."},{"key":"722_CR54","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ng.2996","volume":"46","author":"L Kautz","year":"2014","unstructured":"Kautz, L. et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 46, 678\u2013684 (2014).","journal-title":"Nat. Genet."},{"key":"722_CR55","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","volume":"126","author":"L Kautz","year":"2015","unstructured":"Kautz, L. et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of \u03b2-thalassemia. Blood 126, 2031\u20132037 (2015).","journal-title":"Blood"},{"key":"722_CR56","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1182\/bloodadvances.2022009307","volume":"7","author":"J Olivera","year":"2023","unstructured":"Olivera, J., Zhang, V., Nemeth, E. & Ganz, T. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of \u03b2-thalassemia. Blood Adv. 7, 3339\u20133349 (2023).","journal-title":"Blood Adv."},{"key":"722_CR57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1182\/blood.2019003140","volume":"135","author":"J Arezes","year":"2020","unstructured":"Arezes, J. et al. Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia. Blood 135, 547\u2013557 (2020).","journal-title":"Blood"},{"key":"722_CR58","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood.2023022724","volume":"143","author":"U Sardo","year":"2024","unstructured":"Sardo, U. et al. The hepatokine FGL1 regulates hepcidin and iron metabolism during anemia in mice by antagonizing BMP signaling. Blood 143, 1282\u20131292 (2024).","journal-title":"Blood"},{"key":"722_CR59","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/ejhg.2014.131","volume":"23","author":"J Traeger-Synodinos","year":"2015","unstructured":"Traeger-Synodinos, J. et al. EMQN best practice guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies. Eur. J. Hum. Genet. 23, 426\u2013437 (2015).","journal-title":"Eur. J. Hum. Genet."},{"key":"722_CR60","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17474086.2021.1977116","volume":"14","author":"AT Taher","year":"2021","unstructured":"Taher, A. T., Bou-Fakhredin, R., Kattamis, A., Viprakasit, V. & Cappellini, M. D. Improving outcomes and quality of life for patients with transfusion-dependent \u03b2-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Rev. Hematol. 14, 897\u2013909 (2021).","journal-title":"Expert Rev. Hematol."},{"key":"722_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1179\/102453309X446126","volume":"14","author":"V Sharma","year":"2009","unstructured":"Sharma, V., Kumar, B., Kumar, G. & Saxena, R. Alpha globin gene numbers: an important modifier of HbE\/\u03b2 thalassemia. Hematology 14, 297\u2013300 (2009).","journal-title":"Hematology"},{"key":"722_CR62","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/jha2.262","volume":"2","author":"M Hamid","year":"2021","unstructured":"Hamid, M. et al. Alpha-globin gene triplication and its effect in beta-thalassemia carrier, sickle cell trait, and healthy individual. eJHaem 2, 366\u2013374 (2021).","journal-title":"eJHaem"},{"key":"722_CR63","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1046\/j.1365-2141.2003.04346.x","volume":"121","author":"CA Fisher","year":"2003","unstructured":"Fisher, C. A. et al. The molecular basis for the thalassaemias in Sri Lanka. Br. J. Haematol. 121, 662\u2013671 (2003).","journal-title":"Br. J. Haematol."},{"key":"722_CR64","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/asheducation-2013.1.354","volume":"2013","author":"SL Thein","year":"2013","unstructured":"Thein, S. L. Genetic association studies in \u03b2-hemoglobinopathies. Hematology 2013, 354\u2013361 (2013).","journal-title":"Hematology"},{"key":"722_CR65","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.3390\/jcm11185426","volume":"11","author":"G Mandrile","year":"2022","unstructured":"Mandrile, G. et al. First and second level haemoglobinopathies diagnosis: best practices of the Italian society of thalassemia and haemoglobinopathies (SITE). J. Clin. Med. 11, 5426 (2022).","journal-title":"J. Clin. Med."},{"key":"722_CR66","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fmolb.2020.00074","volume":"7","author":"T Munkongdee","year":"2020","unstructured":"Munkongdee, T., Chen, P., Winichagoon, P., Fucharoen, S. & Paiboonsukwong, K. Update in laboratory diagnosis of thalassemia. Front. Mol. Biosci. 7, 74 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"722_CR67","doi-asserted-by":"publisher","first-page":"em501","DOI":"10.29333\/ejgm\/13206","volume":"20","author":"D Tran","year":"2023","unstructured":"Tran, D. et al. Prevalence of thalassemia in the Vietnamese population and building a clinical decision support system for prenatal screening for thalassemia. Electron. J. Gen. Med. 20, em501 (2023).","journal-title":"Electron. J. Gen. Med."},{"key":"722_CR68","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/diagnostics13091551","volume":"13","author":"K Ferih","year":"2023","unstructured":"Ferih, K. et al. Applications of artificial intelligence in thalassemia: a comprehensive review. Diagnostics 13, 1551 (2023).","journal-title":"Diagnostics"},{"key":"722_CR69","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clp.2025.06.007","volume":"52","author":"BL Therrell","year":"2025","unstructured":"Therrell, B. L. Newborn screening for hemoglobin disorders. Clin. Perinatol. 52, 461\u2013476 (2025).","journal-title":"Clin. Perinatol."},{"key":"722_CR70","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.0064","volume":"6","author":"MO Quarmyne","year":"2025","unstructured":"Quarmyne, M. O. et al. Newborn screening for sickle cell disease and thalassemia. JAMA Health Forum 6, e250064 (2025).","journal-title":"JAMA Health Forum"},{"key":"722_CR71","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/jclinpath-2019-206317","volume":"73","author":"LG Weil","year":"2020","unstructured":"Weil, L. G., Charlton, M. R., Coppinger, C., Daniel, Y. & Streetly, A. Sickle cell disease and thalassaemia antenatal screening programme in England over 10 years: a review from 2007\/2008 to 2016\/2017. J. Clin. Pathol. 73, 183\u2013190 (2020).","journal-title":"J. Clin. Pathol."},{"key":"722_CR72","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/03630269.2021.1872612","volume":"45","author":"M Angastiniotis","year":"2021","unstructured":"Angastiniotis, M. et al. The prevention of thalassemia revisited: a historical and ethical perspective by the Thalassemia International Federation. Hemoglobin 45, 5\u201312 (2021).","journal-title":"Hemoglobin"},{"key":"722_CR73","doi-asserted-by":"publisher","first-page":"7475","DOI":"10.4081\/thal.2018.7475","volume":"8","author":"M Petrou","year":"2018","unstructured":"Petrou, M. Informed choice in a multicultural world. Thalass. Rep. 8, 7475 (2018).","journal-title":"Thalass. Rep."},{"key":"722_CR74","first-page":"58","volume":"27","author":"T Noori","year":"2019","unstructured":"Noori, T. et al. International comparison of thalassemia registries: challenges and opportunities. Acta Inform. Med. 27, 58\u201363 (2019).","journal-title":"Acta Inform. Med."},{"key":"722_CR75","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/03630269.2022.2099285","volume":"46","author":"D Farmakis","year":"2022","unstructured":"Farmakis, D., Angastiniotis, M., El Ghoul, M. M., Cannon, L. & Eleftheriou, A. Thalassaemia registries: a call for action. a position statement from the Thalassaemia International Federation. Hemoglobin 46, 225\u2013232 (2022).","journal-title":"Hemoglobin"},{"key":"722_CR76","unstructured":"Taher, A. T., Farmakis, D., Porter, J. B., Cappellini, M. D. & Musallam, K. M. (eds) Guidelines for the Management of Transfusion-Dependent \u03b2-Thalassaemia (TDT) 5th edn (Thalassaemia International Federation, 2025)."},{"key":"722_CR77","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2141.1995.tb08351.x","volume":"89","author":"M Cazzola","year":"1995","unstructured":"Cazzola, M. et al. Relationship between transfusion regimen and suppression of erythropoiesis in \u03b2-thalassaemia major. Br. J. Haematol. 89, 473\u2013478 (1995).","journal-title":"Br. J. Haematol."},{"key":"722_CR78","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1182\/blood.2023022460","volume":"143","author":"KM Musallam","year":"2024","unstructured":"Musallam, K. M. et al. Pretransfusion hemoglobin level and mortality in adults with transfusion-dependent \u03b2-thalassemia. Blood 143, 930\u2013932 (2024).","journal-title":"Blood"},{"key":"722_CR79","first-page":"108","volume":"11","author":"V Viprakasit","year":"2013","unstructured":"Viprakasit, V. et al. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus. 11, 108\u2013122 (2013).","journal-title":"Blood Transfus."},{"key":"722_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101138","volume":"63","author":"A El-Beshlawy","year":"2024","unstructured":"El-Beshlawy, A. et al. Management of transfusion-dependent \u03b2-thalassemia (TDT): expert insights and practical overview from the Middle East. Blood Rev. 63, 101138 (2024).","journal-title":"Blood Rev."},{"key":"722_CR81","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1111\/trf.16636","volume":"61","author":"CH Tang","year":"2021","unstructured":"Tang, C. H. et al. Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: a real-world analysis. Transfusion 61, 2906\u20132917 (2021).","journal-title":"Transfusion"},{"key":"722_CR82","doi-asserted-by":"publisher","first-page":"E129","DOI":"10.1002\/ajh.25429","volume":"94","author":"M Weiss","year":"2019","unstructured":"Weiss, M., Parisi Jun, M. & Sheth, S. Clinical and economic burden of regularly transfused adult patients with \u03b2-thalassemia in the United States: a retrospective cohort study using payer claims. Am. J. Hematol. 94, E129\u2013E132 (2019).","journal-title":"Am. J. Hematol."},{"key":"722_CR83","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clinthera.2019.12.003","volume":"42","author":"M Betts","year":"2020","unstructured":"Betts, M. et al. Systematic literature review of the burden of disease and treatment for transfusion-dependent \u03b2-thalassemia. Clin. Ther. 42, 322\u2013337.e2 (2020).","journal-title":"Clin. Ther."},{"key":"722_CR84","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ajh.70100","volume":"101","author":"KM Musallam","year":"2026","unstructured":"Musallam, K. M. et al. Quantifying morbidity risk attributed to red-cell transfusion volume in optimally transfused patients with \u03b2-thalassemia. Am. J. Hematol. 101, 149\u2013151 (2026).","journal-title":"Am. J. Hematol."},{"key":"722_CR85","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3324\/haematol.2012.066845","volume":"98","author":"KM Musallam","year":"2013","unstructured":"Musallam, K. M., Rivella, S., Vichinsky, E. & Rachmilewitz, E. A. Non-transfusion-dependent thalassemias. Haematologica 98, 833\u2013844 (2013).","journal-title":"Haematologica"},{"key":"722_CR86","doi-asserted-by":"publisher","first-page":"E78","DOI":"10.1002\/ajh.26428","volume":"97","author":"KM Musallam","year":"2022","unstructured":"Musallam, K. M. et al. Risk of mortality from anemia and iron overload in nontransfusion-dependent \u03b2-thalassemia. Am. J. Hematol. 97, E78\u2013E80 (2022).","journal-title":"Am. J. Hematol."},{"key":"722_CR87","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00277-020-04370-2","volume":"101","author":"KM Musallam","year":"2022","unstructured":"Musallam, K. M., Cappellini, M. D., Daar, S. & Taher, A. T. Morbidity-free survival and hemoglobin level in non-transfusion-dependent \u03b2-thalassemia: a 10-year cohort study. Ann. Hematol. 101, 203\u2013204 (2022).","journal-title":"Ann. Hematol."},{"key":"722_CR88","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00277-021-04456-5","volume":"100","author":"KM Musallam","year":"2021","unstructured":"Musallam, K. M., Cappellini, M. D. & Taher, A. T. Variations in hemoglobin level and morbidity burden in non-transfusion-dependent \u03b2-thalassemia. Ann. Hematol. 100, 1903\u20131905 (2021).","journal-title":"Ann. Hematol."},{"key":"722_CR89","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1182\/blood-2009-09-243154","volume":"115","author":"AT Taher","year":"2010","unstructured":"Taher, A. T. et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 115, 1886\u20131892 (2010).","journal-title":"Blood"},{"key":"722_CR90","unstructured":"Taher, A., Musallam, K. & Cappellini, M. D. (eds) Guidelines for the Management of Non-Transfusion-Dependent \u03b2-Thalassaemia 3rd edn (Thalassaemia International Federation, 2023)."},{"key":"722_CR91","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/j.1538-7836.2010.03940.x","volume":"8","author":"AT Taher","year":"2010","unstructured":"Taher, A. T. et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J. Thromb. Haemost. 8, 2152\u20132158 (2010).","journal-title":"J. Thromb. Haemost."},{"key":"722_CR92","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/ajh.22102","volume":"86","author":"A Piga","year":"2011","unstructured":"Piga, A. et al. Changing patterns of splenectomy in transfusion-dependent thalassemia patients. Am. J. Hematol. 86, 808\u2013810 (2011).","journal-title":"Am. J. Hematol."},{"key":"722_CR93","first-page":"1187","volume":"89","author":"C Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti, C. et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89, 1187\u20131193 (2004).","journal-title":"Haematologica"},{"key":"722_CR94","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJM200008033430503","volume":"343","author":"E Angelucci","year":"2000","unstructured":"Angelucci, E. et al. Hepatic iron concentration and total body iron stores in thalassemia major. N. Engl. J. Med. 343, 327\u2013331 (2000).","journal-title":"N. Engl. J. Med."},{"key":"722_CR95","doi-asserted-by":"publisher","first-page":"E135","DOI":"10.1002\/ajh.25075","volume":"93","author":"V Viprakasit","year":"2018","unstructured":"Viprakasit, V. et al. MRI for the diagnosis of cardiac and liver iron overload in patients with transfusion-dependent thalassemia: an algorithm to guide clinical use when availability is limited. Am. J. Hematol. 93, E135\u2013E137 (2018).","journal-title":"Am. J. Hematol."},{"key":"722_CR96","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1182\/blood-2004-01-0177","volume":"105","author":"TG St Pierre","year":"2005","unstructured":"St Pierre, T. G. et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105, 855\u2013861 (2005).","journal-title":"Blood"},{"key":"722_CR97","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.110.007641","volume":"123","author":"JP Carpenter","year":"2011","unstructured":"Carpenter, J. P. et al. On T2* magnetic resonance and cardiac iron. Circulation 123, 1519\u20131528 (2011).","journal-title":"Circulation"},{"key":"722_CR98","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2004-10-3982","volume":"106","author":"JC Wood","year":"2005","unstructured":"Wood, J. C. et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106, 1460\u20131465 (2005).","journal-title":"Blood"},{"key":"722_CR99","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","volume":"120","author":"P Kirk","year":"2009","unstructured":"Kirk, P. et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120, 1961\u20131968 (2009).","journal-title":"Circulation"},{"key":"722_CR100","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/17474086.2024.2383420","volume":"17","author":"KM Musallam","year":"2024","unstructured":"Musallam, K. M. et al. Anemia and iron overload as prognostic markers of outcomes in \u03b2-thalassemia. Expert Rev. Hematol. 17, 631\u2013642 (2024).","journal-title":"Expert Rev. Hematol."},{"key":"722_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2025.112537","volume":"194","author":"MM Almuqbel","year":"2026","unstructured":"Almuqbel, M. M. et al. Quantitative MRI iron load assessment in \u03b2-thalassemia patients beyond the liver and heart: a systematic review. Eur. J. Radiol. 194, 112537 (2026).","journal-title":"Eur. J. Radiol."},{"key":"722_CR102","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/17474086.2025.2486379","volume":"18","author":"A Meloni","year":"2025","unstructured":"Meloni, A., Positano, V., Ricchi, P., Pepe, A. & Cau, R. What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients? Expert Rev. Hematol. 18, 291\u2013299 (2025).","journal-title":"Expert Rev. Hematol."},{"key":"722_CR103","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17474086.2023.2178409","volume":"16","author":"R Shah","year":"2023","unstructured":"Shah, R., Shah, A. & Badawy, S. M. An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes. Expert Rev. Hematol. 16, 81\u201394 (2023).","journal-title":"Expert Rev. Hematol."},{"key":"722_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31035","volume":"71","author":"GL Forni","year":"2024","unstructured":"Forni, G. L. et al. Iron chelation therapy for children with transfusion-dependent \u03b2-thalassemia: how young is too young? Pediatr. Blood Cancer 71, e31035 (2024).","journal-title":"Pediatr. Blood Cancer"},{"key":"722_CR105","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ajh.24966","volume":"93","author":"MS Elalfy","year":"2018","unstructured":"Elalfy, M. S. et al. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: a randomized controlled trial. Am. J. Hematol. 93, 262\u2013268 (2018).","journal-title":"Am. J. Hematol."},{"key":"722_CR106","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","volume":"123","author":"DJ Pennell","year":"2014","unstructured":"Pennell, D. J. et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in \u03b2-thalassemia major (CORDELIA). Blood 123, 1447\u20131454 (2014).","journal-title":"Blood"},{"key":"722_CR107","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","volume":"107","author":"DJ Pennell","year":"2006","unstructured":"Pennell, D. J. et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107, 3738\u20133744 (2006).","journal-title":"Blood"},{"key":"722_CR108","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","volume":"115","author":"MA Tanner","year":"2007","unstructured":"Tanner, M. A. et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115, 1876\u20131884 (2007).","journal-title":"Circulation"},{"key":"722_CR109","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3324\/haematol.2011.049957","volume":"97","author":"DJ Pennell","year":"2012","unstructured":"Pennell, D. J. et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with \u03b2-thalassemia major. Haematologica 97, 842\u2013848 (2012).","journal-title":"Haematologica"},{"key":"722_CR110","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","volume":"118","author":"MD Cappellini","year":"2011","unstructured":"Cappellini, M. D. et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years\u2019 follow-up. Blood 118, 884\u2013893 (2011).","journal-title":"Blood"},{"key":"722_CR111","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","volume":"28","author":"A Maggio","year":"2002","unstructured":"Maggio, A. et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cell Mol. Dis. 28, 196\u2013208 (2002).","journal-title":"Blood Cell Mol. Dis."},{"key":"722_CR112","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/ajh.24668","volume":"92","author":"AT Taher","year":"2017","unstructured":"Taher, A. T. et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: results of the randomized, phase II ECLIPSE study. Am. J. Hematol. 92, 420\u2013428 (2017).","journal-title":"Am. J. Hematol."},{"key":"722_CR113","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S2352-3026(20)30100-9","volume":"7","author":"A Maggio","year":"2020","unstructured":"Maggio, A. et al. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol. 7, e469\u2013e478 (2020).","journal-title":"Lancet Haematol."},{"key":"722_CR114","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3324\/haematol.2023.283133","volume":"109","author":"AT Taher","year":"2024","unstructured":"Taher, A. T. et al. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study. Haematologica 109, 1413\u20131425 (2024).","journal-title":"Haematologica"},{"key":"722_CR115","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2018-07-815928","volume":"133","author":"S Rivella","year":"2019","unstructured":"Rivella, S. Iron metabolism under conditions of ineffective erythropoiesis in \u03b2-thalassemia. Blood 133, 51\u201358 (2019).","journal-title":"Blood"},{"key":"722_CR116","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.3324\/haematol.2013.097220","volume":"99","author":"KM Musallam","year":"2014","unstructured":"Musallam, K. M. et al. Serum ferritin level and morbidity risk in transfusion-independent patients with \u03b2-thalassemia intermedia: the ORIENT study. Haematologica 99, e218\u2013e221 (2014).","journal-title":"Haematologica"},{"key":"722_CR117","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bcmd.2013.01.015","volume":"51","author":"KM Musallam","year":"2013","unstructured":"Musallam, K. M., Cappellini, M. D. & Taher, A. T. Evaluation of the 5mg\/g liver iron concentration threshold and its association with morbidity in patients with \u03b2-thalassemia intermedia. Blood Cell Mol. Dis. 51, 35\u201338 (2013).","journal-title":"Blood Cell Mol. Dis."},{"key":"722_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101165","volume":"64","author":"KM Musallam","year":"2024","unstructured":"Musallam, K. M. et al. Alpha-thalassemia: a practical overview. Blood Rev. 64, 101165 (2024).","journal-title":"Blood Rev."},{"key":"722_CR119","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/jha2.882","volume":"5","author":"KM Musallam","year":"2024","unstructured":"Musallam, K. M. et al. Systematic review and evidence gap assessment of the clinical, quality of life, and economic burden of alpha-thalassemia. eJHaem 5, 541\u2013547 (2024).","journal-title":"eJHaem"},{"key":"722_CR120","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ajh.26798","volume":"98","author":"GL Forni","year":"2023","unstructured":"Forni, G. L. et al. Overall and complication-free survival in a large cohort of patients with \u03b2-thalassemia major followed over 50 years. Am. J. Hematol. 98, 381\u2013387 (2023).","journal-title":"Am. J. Hematol."},{"key":"722_CR121","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00277-018-3493-4","volume":"98","author":"E Voskaridou","year":"2019","unstructured":"Voskaridou, E. et al. National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality. Ann. Hematol. 98, 55\u201366 (2019).","journal-title":"Ann. Hematol."},{"key":"722_CR122","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1182\/blood-2018-06-818187","volume":"132","author":"AT Taher","year":"2018","unstructured":"Taher, A. T. & Cappellini, M. D. How I manage medical complications of \u03b2-thalassemia in adults. Blood 132, 1781\u20131791 (2018).","journal-title":"Blood"},{"key":"722_CR123","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ajh.21398","volume":"84","author":"GL Forni","year":"2009","unstructured":"Forni, G. L., Puntoni, M., Boeri, E., Terenzani, L. & Balocco, M. The influence of treatment in specialized centers on survival of patients with thalassemia major. Am. J. Hematol. 84, 317\u2013318 (2009).","journal-title":"Am. J. Hematol."},{"key":"722_CR124","unstructured":"Amid, A., Lal, A., Coates, T. D. & Fucharoen, S. (eds) Guidelines for the Management of \u03b1-Thalassemia (Thalassaemia International Federation, 2023)."},{"key":"722_CR125","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/ajh.26316","volume":"96","author":"KM Musallam","year":"2021","unstructured":"Musallam, K. M., Bou-Fakhredin, R., Cappellini, M. D. & Taher, A. T. 2021 update on clinical trials in \u03b2-thalassemia. Am. J. Hematol. 96, 1518\u20131531 (2021).","journal-title":"Am. J. Hematol."},{"key":"722_CR126","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1182\/blood.2023022193","volume":"144","author":"VM Pinto","year":"2024","unstructured":"Pinto, V. M., Mazzi, F. & De Franceschi, L. Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders. Blood 144, 853\u2013866 (2024).","journal-title":"Blood"},{"key":"722_CR127","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","volume":"121","author":"KM Musallam","year":"2013","unstructured":"Musallam, K. M., Taher, A. T., Cappellini, M. D. & Sankaran, V. G. Clinical experience with fetal hemoglobin induction therapy in patients with \u03b2-thalassemia. Blood 121, 2199\u20132212 (2013).","journal-title":"Blood"},{"key":"722_CR128","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood-2011-03-341909","volume":"118","author":"NF Olivieri","year":"2011","unstructured":"Olivieri, N. F. et al. A pilot study of subcutaneous decitabine in \u03b2-thalassemia intermedia. Blood 118, 2708\u20132711 (2011).","journal-title":"Blood"},{"key":"722_CR129","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221100648","volume":"13","author":"C Zuccato","year":"2022","unstructured":"Zuccato, C. et al. Expression of \u03b3-globin genes in \u03b2-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin). Ther. Adv. Hematol. 13, 20406207221100648 (2022).","journal-title":"Ther. Adv. Hematol."},{"key":"722_CR130","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/08880018.2017.1354948","volume":"34","author":"AH Algiraigri","year":"2017","unstructured":"Algiraigri, A. H., Wright, N. A. M., Paolucci, E. O. & Kassam, A. Hydroxyurea for lifelong transfusion-dependent \u03b2-thalassemia: a meta-analysis. Pediatr. Hematol. Oncol. 34, 435\u2013448 (2017).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"722_CR131","volume":"15","author":"MI Hatamleh","year":"2023","unstructured":"Hatamleh, M. I. et al. Efficacy of hydroxyurea in transfusion-dependent major \u03b2-thalassemia patients: a meta-analysis. Cureus 15, e38135 (2023).","journal-title":"Cureus"},{"key":"722_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40849-4","volume":"13","author":"Z Ali","year":"2023","unstructured":"Ali, Z. et al. Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent \u03b2-thalassemia: results from Thal-Thalido study. Sci. Rep. 13, 13592 (2023).","journal-title":"Sci. Rep."},{"key":"722_CR133","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1182\/bloodadvances.2022007031","volume":"6","author":"SH Ansari","year":"2022","unstructured":"Ansari, S. H. et al. Evaluation of the combination therapy of hydroxyurea and thalidomide in \u03b2-thalassemia. Blood Adv. 6, 6162\u20136168 (2022).","journal-title":"Blood Adv."},{"key":"722_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.814302","volume":"12","author":"Y Lu","year":"2021","unstructured":"Lu, Y., Wei, Z., Yang, G., Lai, Y. & Liu, R. Investigating the efficacy and safety of thalidomide for treating patients with \u03b2-thalassemia: a meta-analysis. Front. Pharmacol. 12, 814302 (2021).","journal-title":"Front. Pharmacol."},{"key":"722_CR135","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41392-021-00811-0","volume":"6","author":"JM Chen","year":"2021","unstructured":"Chen, J. M. et al. Safety and efficacy of thalidomide in patients with transfusion-dependent \u03b2-thalassemia: a randomized clinical trial. Signal Transduct. Target. Ther. 6, 405 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"722_CR136","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04432623 (2025)."},{"key":"722_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2021.102561","volume":"89","author":"BS Pace","year":"2021","unstructured":"Pace, B. S. et al. Benserazide racemate and enantiomers induce fetal globin gene expression in vivo: studies to guide clinical development for beta thalassemia and sickle cell disease. Blood Cell Mol. Dis. 89, 102561 (2021).","journal-title":"Blood Cell Mol. Dis."},{"key":"722_CR138","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1182\/blood-2023-184627","volume":"142","author":"KHM Kuo","year":"2023","unstructured":"Kuo, K. H. M. et al. Initial results in a phase 1b trial of PB-04 in sickle cell disease demonstrate fetal hemoglobin induction, additive activity with hydroxyurea, and improved red blood cell sickling parameters [abstract]. Blood 142, 1148 (2023).","journal-title":"Blood"},{"key":"722_CR139","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.12304","volume":"161","author":"S Fucharoen","year":"2013","unstructured":"Fucharoen, S. et al. A randomized phase I\/II trial of HQK-1001, an oral fetal globin gene inducer, in \u03b2-thalassaemia intermedia and HbE\/\u03b2-thalassaemia. Br. J. Haematol. 161, 587\u2013593 (2013).","journal-title":"Br. J. Haematol."},{"key":"722_CR140","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/bjh.12635","volume":"164","author":"A Inati","year":"2014","unstructured":"Inati, A. et al. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in \u03b2-thalassaemia intermedia. Br. J. Haematol. 164, 456\u2013458 (2014).","journal-title":"Br. J. Haematol."},{"key":"722_CR141","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1182\/blood-2013-11-538470","volume":"123","author":"P Patthamalai","year":"2014","unstructured":"Patthamalai, P. et al. A phase 2 trial of HQK-1001 in HbE-\u03b2 thalassemia demonstrates HbF induction and reduced anemia. Blood 123, 1956\u20131957 (2014).","journal-title":"Blood"},{"key":"722_CR142","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1182\/blood-2021-149481","volume":"138","author":"TT Maciel","year":"2021","unstructured":"Maciel, T. T. et al. PDE9 inhibition by IMR-687 improves markers of beta-thalassemia in the Hbbth1\/th1 experimental mouse model [abstract]. Blood 138, 945 (2021).","journal-title":"Blood"},{"key":"722_CR143","unstructured":"Imara. Imara announces results of interim analyses of tovinontrine (IMR-687) phase 2b clinical trials in sickle cell disease and beta-thalassemia. GlobeNewswire https:\/\/go.nature.com\/44202Os (2026)."},{"key":"722_CR144","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1182\/blood-2017-06-790121","volume":"131","author":"AT Taher","year":"2018","unstructured":"Taher, A. T. et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood 131, 263\u2013265 (2018).","journal-title":"Blood"},{"key":"722_CR145","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bjh.17479","volume":"194","author":"AT Taher","year":"2021","unstructured":"Taher, A. T. et al. Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent \u03b2-thalassaemia. Br. J. Haematol. 194, 474\u2013477 (2021).","journal-title":"Br. J. Haematol."},{"key":"722_CR146","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3324\/haematol.2018.212589","volume":"105","author":"C Casu","year":"2020","unstructured":"Casu, C. et al. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult \u03b2-thalassemia major. Haematologica 105, 1835\u20131844 (2020).","journal-title":"Haematologica"},{"key":"722_CR147","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood-2018-99-110885","volume":"132","author":"J Porter","year":"2018","unstructured":"Porter, J. et al. Effect of LJPC-401 (synthetic human hepcidin) on iron parameters in healthy adults [abstract]. Blood 132, 2336 (2018).","journal-title":"Blood"},{"key":"722_CR148","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03381833 (2021)."},{"key":"722_CR149","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2019-129309","volume":"134","author":"R Taranath","year":"2019","unstructured":"Taranath, R. et al. Regulation of iron homeostasis By PTG-300 improves disease parameters in mouse models for beta-thalassemia and hereditary hemochromatosis [abstract]. Blood 134, 3540 (2019).","journal-title":"Blood"},{"issue":"(Suppl. 1)","key":"722_CR150","first-page":"110","volume":"4","author":"A Lal","year":"2020","unstructured":"Lal, A. et al. A hepcidin mimetic, PTG-300, demonstrates pharmacodynamic effects indicating reduced iron availability in transfusion-dependent beta-thalassemia subjects [abstract]. HemaSphere 4 (Suppl. 1), 110 (2020).","journal-title":"HemaSphere"},{"key":"722_CR151","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/ejh.14243","volume":"113","author":"NB Modi","year":"2024","unstructured":"Modi, N. B., Shames, R., Lickliter, J. D. & Gupta, S. Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: a double-blind first-in-human study. Eur. J. Haematol. 113, 340\u2013350 (2024).","journal-title":"Eur. J. Haematol."},{"key":"722_CR152","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1172\/JCI66969","volume":"123","author":"S Guo","year":"2013","unstructured":"Guo, S. et al. Reducing TMPRSS6 ameliorates hemochromatosis and \u03b2-thalassemia in mice. J. Clin. Invest. 123, 1531\u20131541 (2013).","journal-title":"J. Clin. Invest."},{"key":"722_CR153","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1182\/blood-2018-99-115339","volume":"132","author":"M McCaleb","year":"2018","unstructured":"McCaleb, M. et al. Transmembrane protease, serine 6 (TMPRSS6) antisense oligonucleotide (IONIS-TMPRSS6-LRX) reduces plasma iron levels of healthy volunteers in a phase 1 clinical study [abstract]. Blood 132, 3634 (2018).","journal-title":"Blood"},{"key":"722_CR154","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.3324\/haematol.2022.282328","volume":"108","author":"N Kalleda","year":"2023","unstructured":"Kalleda, N. et al. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of \u03b2-thalassemia with blood transfusions. Haematologica 108, 2703\u20132714 (2023).","journal-title":"Haematologica"},{"key":"722_CR155","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.25670","volume":"95","author":"F Richard","year":"2020","unstructured":"Richard, F. et al. Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers. Am. J. Hematol. 95, 68\u201377 (2020).","journal-title":"Am. J. Hematol."},{"key":"722_CR156","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/01.HS9.0000843980.18213.bf","volume":"6","author":"A Taher","year":"2022","unstructured":"Taher, A., Kourakli-Symeonidis, A., Tantiworawit, A., Wong, P. & Szecs\u00f6dy, P. Safety and preliminary pharmacodynamic effects of the ferroportin inhibitor vamifeport (VIT-2763) in patients with non-transfusion-dependent beta thalassemia (NTDT): results from a phase 2a study [abstract]. HemaSphere 6, 173\u2013174 (2022).","journal-title":"HemaSphere"},{"key":"722_CR157","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04718844 (2024)."},{"key":"722_CR158","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","volume":"121","author":"PJ Schmidt","year":"2013","unstructured":"Schmidt, P. J. et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe\u2212\/\u2212 mice and ameliorates anemia and iron overload in murine \u03b2-thalassemia intermedia. Blood 121, 1200\u20131208 (2013).","journal-title":"Blood"},{"key":"722_CR159","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/ajh.27015","volume":"98","author":"JB Porter","year":"2023","unstructured":"Porter, J. B. et al. SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers. Am. J. Hematol. 98, 1425\u20131435 (2023).","journal-title":"Am. J. Hematol."},{"key":"722_CR160","unstructured":"Business Wire. Silence Therapeutics announces preliminary single dose results from SLN124 phase 1 study in patients with thalassemia. Business Wire https:\/\/www.businesswire.com\/news\/home\/20220929005148\/en\/ (2026)."},{"key":"722_CR161","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RN Suragani","year":"2014","unstructured":"Suragani, R. N. et al. Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat. Med. 20, 408\u2013414 (2014).","journal-title":"Nat. Med."},{"key":"722_CR162","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","volume":"123","author":"RN Suragani","year":"2014","unstructured":"Suragani, R. N. et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine \u03b2-thalassemia. Blood 123, 3864\u20133872 (2014).","journal-title":"Blood"},{"key":"722_CR163","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ajh.23732","volume":"89","author":"KM Attie","year":"2014","unstructured":"Attie, K. M. et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am. J. Hematol. 89, 766\u2013770 (2014).","journal-title":"Am. J. Hematol."},{"key":"722_CR164","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1182\/blood-2018-10-879247","volume":"133","author":"A Piga","year":"2019","unstructured":"Piga, A. et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with \u03b2-thalassemia. Blood 133, 1279\u20131289 (2019).","journal-title":"Blood"},{"key":"722_CR165","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02604433 (2023)."},{"key":"722_CR166","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","volume":"382","author":"MD Cappellini","year":"2020","unstructured":"Cappellini, M. D. et al. A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia. N. Engl. J. Med. 382, 1219\u20131231 (2020).","journal-title":"N. Engl. J. Med."},{"key":"722_CR167","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2352-3026(24)00376-4","volume":"12","author":"MD Cappellini","year":"2025","unstructured":"Cappellini, M. D. et al. Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent \u03b2-thalassaemia (BELIEVE): final results from a phase 3 randomised trial. Lancet Haematol. 12, e180\u2013e189 (2025).","journal-title":"Lancet Haematol."},{"key":"722_CR168","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/ajh.27758","volume":"100","author":"R Origa","year":"2025","unstructured":"Origa R. et al. Luspatercept for transfusion-dependent beta-thalassemia: real-world experience in a large cohort of patients from Italy. Am. J. Hematol. 100, 1651\u20131655 (2025).","journal-title":"Am. J. Hematol."},{"key":"722_CR169","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231195594","volume":"14","author":"KM Musallam","year":"2023","unstructured":"Musallam, K. M. et al. Luspatercept for transfusion-dependent \u03b2-thalassemia: time to get real. Ther. Adv. Hematol. 14, 20406207231195594 (2023).","journal-title":"Ther. Adv. Hematol."},{"key":"722_CR170","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/ajh.27745","volume":"100","author":"KM Musallam","year":"2025","unstructured":"Musallam K. M. Luspatercept in transfusion-dependent \u03b2-thalassemia: the benefit is real, and so are the risks. Am J Hematol. 100, 1480\u20131482 (2025).","journal-title":"Am J Hematol."},{"key":"722_CR171","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04064060 (2025)."},{"key":"722_CR172","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2024-200157","volume":"144","author":"JB Porter","year":"2024","unstructured":"Porter, J. B. et al. Improvement of iron overload parameters in patients with transfusion-dependent \u03b2-thalassemia treated with luspatercept: data from the phase 3b long-term rollover study following the BELIEVE trial [abstract]. Blood 144, 2475 (2024).","journal-title":"Blood"},{"key":"722_CR173","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/ajh.27102","volume":"99","author":"MW Garbowski","year":"2024","unstructured":"Garbowski, M. W. et al. Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia. Am. J. Hematol. 99, 182\u2013192 (2024).","journal-title":"Am. J. Hematol."},{"key":"722_CR174","doi-asserted-by":"publisher","first-page":"8215","DOI":"10.1182\/blood-2022-156985","volume":"140","author":"O Hermine","year":"2022","unstructured":"Hermine, O. et al. Effect of luspatercept on red blood cell (RBC) transfusion burden, iron chelation therapy (ICT), and iron overload in adults with transfusion-dependent \u03b2-thalassemia (TDT) from the believe trial: a long-term analysis [abstract]. Blood 140, 8215\u20138217 (2022).","journal-title":"Blood"},{"key":"722_CR175","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03342404 (2023)."},{"key":"722_CR176","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjh.18801","volume":"201","author":"S Sheth","year":"2023","unstructured":"Sheth, S., Taher, A. T., Coates, T. D., Kattamis, A. & Cappellini, M. D. Management of luspatercept therapy in patients with transfusion-dependent \u03b2-thalassaemia. Br. J. Haematol. 201, 824\u2013831 (2023).","journal-title":"Br. J. Haematol."},{"key":"722_CR177","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/hematology.2024000567","volume":"2024","author":"KM Musallam","year":"2024","unstructured":"Musallam, K. M. & Taher, A. T. Luspatercept: a treatment for ineffective erythropoiesis in thalassemia. Hematology 2024, 419\u2013425 (2024).","journal-title":"Hematology"},{"key":"722_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101103","volume":"61","author":"MJ van Dijk","year":"2023","unstructured":"van Dijk, M. J. et al. Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: shedding new light on an old enzyme. Blood Rev. 61, 101103 (2023).","journal-title":"Blood Rev."},{"key":"722_CR179","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1182\/bloodadvances.2024013591","volume":"9","author":"A Siciliano","year":"2025","unstructured":"Siciliano A. et al. Mitapivat metabolically reprograms human \u03b2-thalassemic erythroblasts, increasing their responsiveness to oxidation. Blood Adv. 9, 2818\u20132830 (2025).","journal-title":"Blood Adv."},{"key":"722_CR180","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.3324\/haematol.2022.282614","volume":"108","author":"A Matte","year":"2023","unstructured":"Matte, A. et al. Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in \u03b2-thalassemic mice. Haematologica 108, 2535\u20132541 (2023).","journal-title":"Haematologica"},{"key":"722_CR181","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144206","volume":"131","author":"A Matte","year":"2021","unstructured":"Matte, A. et al. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a \u03b2-thalassemia mouse model. J. Clin. Invest. 131, e144206 (2021).","journal-title":"J. Clin. Invest."},{"key":"722_CR182","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(22)01337-X","volume":"400","author":"KHM Kuo","year":"2022","unstructured":"Kuo, K. H. M. et al. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent \u03b1-thalassaemia or \u03b2-thalassaemia: an open-label, multicentre, phase 2 study. Lancet 400, 493\u2013501 (2022).","journal-title":"Lancet"},{"key":"722_CR183","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04770753 (2026)."},{"key":"722_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04770779 (2026)."},{"key":"722_CR185","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0140-6736(25)00635-X","volume":"406","author":"AT Taher","year":"2025","unstructured":"Taher A. T. et al. Mitapivat in adults with non-transfusion-dependent alpha-thalassaemia or beta-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial. Lancet 406, 33\u201342 (2025).","journal-title":"Lancet"},{"key":"722_CR186","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1182\/blood-2024-200867","volume":"144","author":"MD Cappellini","year":"2024","unstructured":"Cappellini, M. D. et al. ENERGIZE-T: a global, phase 3, double-blind, randomized, placebo-controlled study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia. Blood 144, 409\u2013411 (2024).","journal-title":"Blood"},{"key":"722_CR187","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04987489 (2025)."},{"key":"722_CR188","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/cpdd.1058","volume":"11","author":"S Forsyth","year":"2022","unstructured":"Forsyth, S. et al. Safety, pharmacokinetics, and pharmacodynamics of etavopivat (FT-4202), an allosteric activator of pyruvate kinase-R, in healthy adults: a randomized, placebo-controlled, double-blind, first-in-human phase 1 trial. Clin. Pharmacol. Drug Dev. 11, 654\u2013665 (2022).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"722_CR189","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1097\/01.HS9.0000851756.51961.79","volume":"6","author":"A Lal","year":"2022","unstructured":"Lal, A. et al. Trial in progress: a phase 2, open-label study evaluating the safety and efficacy of the erythrocyte pyruvate kinase activator etavopivat in patients with thalassemia or sickle cell disease [abstract]. HemaSphere 6, 2102\u20132103 (2022).","journal-title":"HemaSphere"},{"key":"722_CR190","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S2352-3026(25)00320-5","volume":"13","author":"KM Musallam","year":"2026","unstructured":"Musallam, K. M. et al. Management of transfusion-dependent \u03b2-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources. Lancet Haematol. 13, e49\u2013e54 (2026).","journal-title":"Lancet Haematol."},{"key":"722_CR191","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/asheducation-2010.1.456","volume":"2010","author":"E Angelucci","year":"2010","unstructured":"Angelucci, E. Hematopoietic stem cell transplantation in thalassemia. Hematology 2010, 456\u2013462 (2010).","journal-title":"Hematology"},{"key":"722_CR192","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2013.099747","volume":"99","author":"A Emanuele","year":"2014","unstructured":"Emanuele, A. et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 99, 811\u2013820 (2014).","journal-title":"Haematologica"},{"key":"722_CR193","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/bmt.2015.293","volume":"51","author":"D Baronciani","year":"2016","unstructured":"Baronciani, D. et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European society for blood and bone marrow transplantation hemoglobinopathy registry, 2000\u20132010. Bone Marrow Transplant. 51, 536\u2013541 (2016).","journal-title":"Bone Marrow Transplant."},{"issue":"(Suppl. 1)","key":"722_CR194","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood-2018-168","volume":"132","author":"D Baronciani","year":"2018","unstructured":"Baronciani, D. et al. Hematopoietic cell transplantation in thalassemia and sickle cell disease: report from the European society for blood and bone marrow transplantation hemoglobinopathy registry: 2000-2017 [abstract]. Blood 132 (Suppl. 1), 168 (2018).","journal-title":"Blood"},{"key":"722_CR195","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ajh.24674","volume":"92","author":"E Angelucci","year":"2017","unstructured":"Angelucci, E., Pilo, F. & Coates, T. D. Transplantation in thalassemia: revisiting the Pesaro risk factors 25 years later. Am. J. Hematol. 92, 411\u2013413 (2017).","journal-title":"Am. J. Hematol."},{"key":"722_CR196","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2005-08-3374","volume":"107","author":"K Fleischhauer","year":"2006","unstructured":"Fleischhauer, K. et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 107, 2984\u20132992 (2006).","journal-title":"Blood"},{"key":"722_CR197","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.hoc.2022.12.009","volume":"37","author":"M Algeri","year":"2023","unstructured":"Algeri, M., Lodi, M. & Locatelli, F. Hematopoietic stem cell transplantation in thalassemia. Hematol. Oncol. Clin. N. Am. 37, 413\u2013432 (2023).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"722_CR198","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.2023023692","volume":"144","author":"A Amid","year":"2024","unstructured":"Amid, A., Liu, S., Babbs, C. & Higgs, D. R. Hemoglobin Bart\u2019s hydrops fetalis: charting the past and envisioning the future. Blood 144, 822\u2013833 (2024).","journal-title":"Blood"},{"key":"722_CR199","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson, A. A. et al. Gene therapy in patients with transfusion-dependent \u03b2-thalassemia. N. Engl. J. Med. 378, 1479\u20131493 (2018).","journal-title":"N. Engl. J. Med."},{"key":"722_CR200","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02906202 (2023)."},{"key":"722_CR201","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa2113206","volume":"386","author":"F Locatelli","year":"2022","unstructured":"Locatelli, F. et al. Betibeglogene autotemcel gene therapy for \u03b20\/\u03b20 genotype \u03b2-thalassemia. N. Engl. J. Med. 386, 415\u2013427 (2022).","journal-title":"N. Engl. J. Med."},{"key":"722_CR202","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03207009 (2024)."},{"key":"722_CR203","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","volume":"404","author":"JL Kwiatkowski","year":"2024","unstructured":"Kwiatkowski, J. L. et al. Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. Lancet 404, 2175\u20132186 (2024).","journal-title":"Lancet"},{"key":"722_CR204","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02633943 (2025)."},{"key":"722_CR205","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41591-021-01650-w","volume":"28","author":"E Magrin","year":"2022","unstructured":"Magrin, E. et al. Long-term outcomes of lentiviral gene therapy for the \u03b2-hemoglobinopathies: the HGB-205 trial. Nat. Med. 28, 81\u201388 (2022).","journal-title":"Nat. Med."},{"key":"722_CR206","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41591-018-0301-6","volume":"25","author":"S Marktel","year":"2019","unstructured":"Marktel, S. et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent \u03b2-thalassemia. Nat. Med. 25, 234\u2013241 (2019).","journal-title":"Nat. Med."},{"key":"722_CR207","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41591-021-01554-9","volume":"28","author":"F Boulad","year":"2022","unstructured":"Boulad, F. et al. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with \u03b2-thalassemia: a phase 1 trial. Nat. Med. 28, 63\u201370 (2022).","journal-title":"Nat. Med."},{"key":"722_CR208","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1126\/science.1165409","volume":"322","author":"VG Sankaran","year":"2008","unstructured":"Sankaran, V. G. et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322, 1839\u20131842 (2008).","journal-title":"Science"},{"key":"722_CR209","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","volume":"127","author":"MD Hoban","year":"2016","unstructured":"Hoban, M. D., Orkin, S. H. & Bauer, D. E. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood 127, 839\u2013848 (2016).","journal-title":"Blood"},{"key":"722_CR210","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1126\/science.1242088","volume":"342","author":"DE Bauer","year":"2013","unstructured":"Bauer, D. E. et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 342, 253\u2013257 (2013).","journal-title":"Science"},{"key":"722_CR211","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N. Engl. J. Med. 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med."},{"key":"722_CR212","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03655678 (2025)."},{"key":"722_CR213","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04208529 (2026)."},{"key":"722_CR214","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1182\/blood-2024-205779","volume":"144","author":"F Locatelli","year":"2024","unstructured":"Locatelli, F. et al. Durable clinical benefits with exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia [abstract]. Blood 144, 512 (2024).","journal-title":"Blood"},{"key":"722_CR215","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli, F. et al. Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia. N. Engl. J. Med. 390, 1663\u20131676 (2024).","journal-title":"N. Engl. J. Med."},{"key":"722_CR216","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03432364 (2023)."},{"key":"722_CR217","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1182\/blood-2021-147907","volume":"138","author":"MC Walters","year":"2021","unstructured":"Walters, M. C. et al. Updated results of a phase 1\/2 clinical study of zinc finger nuclease-mediated editing of BCL11A in autologous hematopoietic stem cells for transfusion-dependent beta thalassemia [abstract]. Blood 138, 3974 (2021).","journal-title":"Blood"},{"key":"722_CR218","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05444894 (2025)."},{"key":"722_CR219","first-page":"2727","volume":"8","author":"H Franghoul","year":"2024","unstructured":"Franghoul, H. et al. Reni-cel, the first AsCas12a gene-edited cell therapy, shows promising preliminary results in key clinical outcomes in transfusion-dependent beta-thalassemia patients treated in the EDITHAL trial [abstract]. HemaSphere 8, 2727\u20132728 (2024).","journal-title":"HemaSphere"},{"key":"722_CR220","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","volume":"19","author":"HA Rees","year":"2018","unstructured":"Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat. Rev. Genet. 19, 770\u2013788 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"722_CR221","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.hoc.2022.12.012","volume":"37","author":"GE Christakopoulos","year":"2023","unstructured":"Christakopoulos, G. E., Telange, R., Yen, J. & Weiss, M. J. Gene therapy and gene editing for beta-thalassemia. Hematol. Oncol. Clin. N. Am. 37, 433\u2013447 (2023).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"722_CR222","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1182\/blood-2024-204888","volume":"144","author":"AO Gupta","year":"2024","unstructured":"Gupta, A. O. et al. Initial results from the BEACON clinical study: a phase 1\/2 study evaluating the safety and efficacy of a single dose of autologous CD34+ base edited hematopoietic stem cells (BEAM-101) in patients with sickle cell disease with severe vaso-occlusive crises [abstract]. Blood 144, 513 (2024).","journal-title":"Blood"},{"key":"722_CR223","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2022016629","volume":"141","author":"G Hardouin","year":"2023","unstructured":"Hardouin, G. et al. Adenine base editor-mediated correction of the common and severe IVS1-110 (G>A) beta-thalassemia mutation. Blood 141, 1169\u20131179 (2023).","journal-title":"Blood"},{"key":"722_CR224","doi-asserted-by":"publisher","first-page":"e421","DOI":"10.1097\/MPH.0000000000001573","volume":"41","author":"T Radke","year":"2019","unstructured":"Radke, T., Paulukonis, S., Hulihan, M. M. & Feuchtbaum, L. Providers\u2019 perspectives on treating patients with thalassemia. J. Pediatr. Hematol. Oncol. 41, e421\u2013e426 (2019).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"722_CR225","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/nyas.15100","volume":"1532","author":"R Shah","year":"2024","unstructured":"Shah, R. & Badawy, S. M. Health-related quality of life with standard and curative therapies in thalassemia: a narrative literature review. Ann. N. Y. Acad. Sci. 1532, 50\u201362 (2024).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"722_CR226","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/ajh.21896","volume":"86","author":"A Sobota","year":"2011","unstructured":"Sobota, A. et al. Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am. J. Hematol. 86, 92\u201395 (2011).","journal-title":"Am. J. Hematol."},{"key":"722_CR227","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-0609.2011.01623.x","volume":"87","author":"KM Musallam","year":"2011","unstructured":"Musallam, K. M. et al. Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur. J. Haematol. 87, 73\u201379 (2011).","journal-title":"Eur. J. Haematol."},{"key":"722_CR228","doi-asserted-by":"publisher","first-page":"E261","DOI":"10.1002\/ajh.25584","volume":"94","author":"MD Cappellini","year":"2019","unstructured":"Cappellini, M. D. et al. Quality of life in patients with \u03b2-thalassemia: a prospective study of transfusion-dependent and non-transfusion-dependent patients in Greece, Italy, Lebanon, and Thailand. Am. J. Hematol. 94, E261\u2013E264 (2019).","journal-title":"Am. J. Hematol."},{"key":"722_CR229","first-page":"1","volume":"10","author":"M Thavorncharoensap","year":"2010","unstructured":"Thavorncharoensap, M. et al. Factors affecting health-related quality of life in Thai children with thalassemia. BMC Blood Disord. 10, 1 (2010).","journal-title":"BMC Blood Disord."},{"key":"722_CR230","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/03630269.2021.1965617","volume":"45","author":"K Etemad","year":"2021","unstructured":"Etemad, K. et al. Quality of life and related factors in \u03b2-thalassemia patients. Hemoglobin 45, 245\u2013249 (2021).","journal-title":"Hemoglobin"},{"key":"722_CR231","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1182\/asheducation-2017.1.272","volume":"2017","author":"A Piga","year":"2017","unstructured":"Piga, A. Impact of bone disease and pain in thalassemia. Hematology 2017, 272\u2013277 (2017).","journal-title":"Hematology"},{"key":"722_CR232","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231167050","volume":"14","author":"M Bu","year":"2023","unstructured":"Bu, M. et al. Brain iron content and cognitive function in patients with \u03b2-thalassemia. Ther. Adv. Hematol. 14, 20406207231167050 (2023).","journal-title":"Ther. Adv. Hematol."},{"key":"722_CR233","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101181","volume":"65","author":"M Bizri","year":"2024","unstructured":"Bizri, M. et al. Quality of life, mood disorders, and cognitive impairment in adults with \u03b2-thalassemia. Blood Rev. 65, 101181 (2024).","journal-title":"Blood Rev."},{"key":"722_CR234","doi-asserted-by":"publisher","DOI":"10.1177\/23779608251323811","volume":"11","author":"K Wangi","year":"2025","unstructured":"Wangi, K., Shaleha, R., Wijaya, E. & Birriel, B. Psychosocial problems in people living with thalassemia: a systematic review. SAGE Open Nurs. 11, 23779608251323811 (2025).","journal-title":"SAGE Open Nurs."},{"key":"722_CR235","doi-asserted-by":"publisher","unstructured":"Greco, F. & Marino, F. Social impact and quality of life of patients with \u03b2-thalassaemia: a systematic review. EMJ Hematol. https:\/\/doi.org\/10.33590\/emjhematol\/22-00041 (2022).","DOI":"10.33590\/emjhematol\/22-00041"},{"key":"722_CR236","first-page":"225","volume":"90","author":"V De Sanctis","year":"2019","unstructured":"De Sanctis, V. et al. Marital status and paternity in patients with transfusion-dependent thalassemia (TDT) and non transfusion-dependent thalassemia (NTDT): an ICET - a survey in different countries. Acta Biomed. 90, 225\u2013237 (2019).","journal-title":"Acta Biomed."},{"key":"722_CR237","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/medicina60040650","volume":"60","author":"EC Economidou","year":"2024","unstructured":"Economidou, E. C., Angastiniotis, M., Avraam, D., Soteriades, E. S. & Eleftheriou, A. Addressing thalassaemia management from patients\u2019 perspectives: an international collaborative assessment. Medicina 60, 650 (2024).","journal-title":"Medicina"},{"key":"722_CR238","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/jgc4.1231","volume":"29","author":"FK Boardman","year":"2020","unstructured":"Boardman, F. K., Clark, C., Jungkurth, E. & Young, P. J. Social and cultural influences on genetic screening programme acceptability: a mixed-methods study of the views of adults, carriers, and family members living with thalassemia in the UK. J. Genet. Couns. 29, 1026\u20131040 (2020).","journal-title":"J. Genet. Couns."},{"key":"722_CR239","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/nyas.15097","volume":"1532","author":"M Angastiniotis","year":"2024","unstructured":"Angastiniotis, M. Beta thalassemia: looking to the future, addressing unmet needs and challenges. Ann. N. Y. Acad. Sci. 1532, 63\u201372 (2024).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"722_CR240","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1080\/13696998.2023.2235928","volume":"26","author":"C Udeze","year":"2023","unstructured":"Udeze, C. et al. Economic and clinical burden of managing transfusion-dependent \u03b2-thalassemia in the United States. J. Med. Econ. 26, 924\u2013932 (2023).","journal-title":"J. Med. Econ."},{"key":"722_CR241","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/03630269.2023.2167657","volume":"46","author":"A Eleftheriou","year":"2022","unstructured":"Eleftheriou, A. et al. Estimating the cost of thalassemia care across the world: a Thalassemia International Federation model. Hemoglobin 46, 308\u2013311 (2022).","journal-title":"Hemoglobin"},{"key":"722_CR242","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/trf.13513","volume":"56","author":"D Weidlich","year":"2016","unstructured":"Weidlich, D., Kefalas, P. & Guest, J. F. Healthcare costs and outcomes of managing \u03b2-thalassemia major over 50 years in the United Kingdom. Transfusion 56, 1038\u20131045 (2016).","journal-title":"Transfusion"},{"key":"722_CR243","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.886674","volume":"10","author":"F Rodigari","year":"2022","unstructured":"Rodigari, F., Brugnera, G. & Colombatti, R. Health-related quality of life in hemoglobinopathies: a systematic review from a global perspective. Front. Pediatr. 10, 886674 (2022).","journal-title":"Front. Pediatr."},{"key":"722_CR244","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s11136-025-03961-8","volume":"34","author":"J Drahos","year":"2025","unstructured":"Drahos, J. et al. Health-related quality of life and economic impacts in adults with transfusion-dependent \u03b2-thalassemia: findings from a prospective longitudinal real-world study. Qual. Life Res. 34, 2005\u20132017 (2025).","journal-title":"Qual. Life Res."},{"key":"722_CR245","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMp2403596","volume":"391","author":"JW Jacobs","year":"2024","unstructured":"Jacobs, J. W. et al. Ensuring a safe and sufficient global blood supply. N. Engl. J. Med. 391, 1079\u20131081 (2024).","journal-title":"N. Engl. J. Med."},{"key":"722_CR246","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1016\/S2214-109X(23)00564-8","volume":"12","author":"NP Raykar","year":"2024","unstructured":"Raykar, N. P. et al. Innovative blood transfusion strategies to address global blood deserts: a consensus statement from the blood delivery via emerging strategies for emergency remote transfusion (blood DESERT) coalition. Lancet Glob. Health 12, e522\u2013e529 (2024).","journal-title":"Lancet Glob. Health"},{"key":"722_CR247","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/trf.14598","volume":"58","author":"B Custer","year":"2018","unstructured":"Custer, B. et al. Addressing gaps in international blood availability and transfusion safety in low- and middle-income countries: a NHLBI workshop. Transfusion 58, 1307\u20131317 (2018).","journal-title":"Transfusion"},{"key":"722_CR248","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/17474086.2025.2489562","volume":"18","author":"LE Wang","year":"2025","unstructured":"Wang, L. E., Muttar, S. & Badawy, S. M. The challenges of iron chelation therapy in thalassemia: how do we overcome them? Expert Rev. Hematol. 18, 351\u2013357 (2025).","journal-title":"Expert Rev. Hematol."},{"key":"722_CR249","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1056\/NEJMra050436","volume":"353","author":"D Rund","year":"2005","unstructured":"Rund, D. & Rachmilewitz, E. \u03b2-Thalassemia. N. Engl. J. Med. 353, 1135\u20131146 (2005).","journal-title":"N. Engl. J. Med."},{"key":"722_CR250","unstructured":"Hoffman, R. et al. (eds) Hematology: Basic Principles and Practice 5th edn (Elsevier, 2008)."},{"key":"722_CR251","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.hoc.2022.12.001","volume":"37","author":"N Tesio","year":"2023","unstructured":"Tesio, N. & Bauer, D. Molecular basis and genetic modifiers of thalassemia. Hematol. Oncol. Clin. N. Am. 37, 273\u2013299 (2023).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"722_CR252","unstructured":"United Nations Department of Social and Economic Affairs Population Division. World Population Prospects (UNDESA, accessed 14th June 2024); https:\/\/population.un.org\/wpp\/."},{"key":"722_CR253","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41431-022-01051-8","volume":"30","author":"ME van Vliet","year":"2022","unstructured":"van Vliet, M. E., Kerkhoffs, J. H., Harteveld, C. L. & Houwink, E. J. F. Hemoglobinopathy prevention in primary care: a reflection of underdetection and difficulties with accessibility of medical care, a quantitative study. Eur. J. Hum. Genet. 30, 790\u2013794 (2022).","journal-title":"Eur. J. Hum. Genet."},{"key":"722_CR254","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/cge.14606","volume":"107","author":"E Shchemeleva","year":"2025","unstructured":"Shchemeleva, E. et al. Active spread of \u03b2-thalassemia beyond the thalassemia belt: a study on a Russian population. Clin. Genet. 107, 23\u201333 (2025).","journal-title":"Clin. Genet."},{"key":"722_CR255","first-page":"261","volume":"19","author":"F Longo","year":"2021","unstructured":"Longo, F. et al. Changing patterns of thalassaemia in Italy: a WebThal perspective. Blood Transfus. 19, 261\u2013268 (2021).","journal-title":"Blood Transfus."},{"key":"722_CR256","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1323-y","volume":"15","author":"MS Hossain","year":"2020","unstructured":"Hossain, M. S. et al. Lack of knowledge and misperceptions about thalassaemia among college students in Bangladesh: a cross-sectional baseline study. Orphanet J. Rare Dis. 15, 54 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"722_CR257","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078637","volume":"386","author":"Y An","year":"2024","unstructured":"An, Y., Shen, Y., Ma, Y. & Wang, H. Research needs for birth defect prevention and control in China in the genomic screening era. BMJ 386, e078637 (2024).","journal-title":"BMJ"},{"key":"722_CR258","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120151","volume":"569","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. Thalassemia genetic screening of pregnant women with anemia in Northern China through comprehensive analysis of thalassemia alleles (CATSA). Clin. Chim. Acta 569, 120151 (2025).","journal-title":"Clin. Chim. Acta"},{"key":"722_CR259","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70095","volume":"9","author":"KM Musallam","year":"2025","unstructured":"Musallam, K. M. et al. TIF guidelines for the management of transfusion-dependent \u03b2-thalassemia. HemaSphere 9, e70095 (2025).","journal-title":"HemaSphere"},{"key":"722_CR260","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1111\/bjh.19362","volume":"204","author":"FT Shah","year":"2024","unstructured":"Shah, F. T. et al. Guideline for the management of conception and pregnancy in thalassaemia syndromes: a British society for haematology guideline. Br. J. Haematol. 204, 2194\u20132209 (2024).","journal-title":"Br. J. Haematol."},{"key":"722_CR261","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/jcm14030948","volume":"14","author":"VM Pinto","year":"2025","unstructured":"Pinto, V. M. et al. Thalassemias and sickle cell diseases in pregnancy: site good practice. J. Clin. Med. 14, 948 (2025).","journal-title":"J. Clin. Med."},{"key":"722_CR262","first-page":"377","volume":"27","author":"Committee of Thalassemia Prevention and Treatment, China Maternal and Child Health Association, Subspecialty Group of Hematology, Society of Pediatrics, Chinese Medical Association, China Thalassemia Prevention and Control Collaboration Network & Editorial Board of Chinese Journal of Contemporary Pediatrics.","year":"2025","unstructured":"Committee of Thalassemia Prevention and Treatment, China Maternal and Child Health Association, Subspecialty Group of Hematology, Society of Pediatrics, Chinese Medical Association, China Thalassemia Prevention and Control Collaboration Network & Editorial Board of Chinese Journal of Contemporary Pediatrics. Guidelines for iron chelation therapy in thalassemia in China (2025). Chin. J. Contemp. Pediatr. 27, 377\u2013388 (2025).","journal-title":"Chin. J. Contemp. Pediatr."},{"key":"722_CR263","first-page":"495","volume":"113","author":"M Casale","year":"2022","unstructured":"Casale, M. et al. The management of endocrine complications in patients with haemoglobinopathies: good clinical practice of the Italian society of thalassemia and haemoglobinopathies (SITE). Recenti Prog. Med. 113, 495\u2013554 (2022).","journal-title":"Recenti Prog. Med."},{"key":"722_CR264","unstructured":"National Health Mission. Prevention and Control of Haemoglobinopathies in India \u2013 Thalassemias, Sickle Cell Disease and Other Variant Hemoglobins (Ministry of Health & Family Welfare, Government of India, 2016)."},{"key":"722_CR265","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000345734","volume":"130","author":"KM Musallam","year":"2013","unstructured":"Musallam, K. M., Angastiniotis, M., Eleftheriou, A. & Porter, J. B. Cross-talk between available guidelines for the management of patients with beta-thalassemia major. Acta Haematol. 130, 64\u201373 (2013).","journal-title":"Acta Haematol."}],"updated-by":[{"DOI":"10.1038\/s41572-026-00756-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:00:00Z","timestamp":1793318400000}}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00722-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00722-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00722-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:02:36Z","timestamp":1793433756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00722-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":265,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1038\/s41572-026-00722-w","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"10 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41572-026-00756-0","URL":"https:\/\/doi.org\/10.1038\/s41572-026-00756-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.B.P. declares financial support from Novo Nordisk for educational activities. He acknowledges infrastructure support for the Department of Epidemiology and Biostatistics provided by the National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre (BRC). He is a member of the MRC Centre for Environment and Health, funded by the UK Medical Research Council (MRC; grant number MR\/S019669\/1). M.d.M. is part of the steering committees of Addmedica\/Theravia and Vertex. She is part of Novo Nordisk\u2019s speakers\u2019 bureau. K.H.M.K. reports grants from Agios Pharmaceuticals and Pfizer; consulting fees from Agios Pharmaceuticals, Alexion Pharmaceuticals, Biossil, Bristol Myers Squibb, Forma, Novo Nordisk, Pfizer and Vertex Therapeutics; honoraria from Agios Pharmaceuticals, Bristol Myers Squibb and Novo Nordisk; and service on a data safety monitoring board and advisory board for Sangamo. A.T.T. reports consultancy fees from Novo Nordisk, Bristol Myers Squibb (Celgene Corp), Agios Pharmaceuticals, Pharmacosmos and Roche and research funding from Novo Nordisk, Bristol Myers Squibb (Celgene Corp), Agios Pharmaceuticals, Pharmacosmos and Roche. K.M.M. reports consultancy fees from Novartis, Bristol Myers Squibb (Celgene Corp), Agios Pharmaceuticals, CRISPR Therapeutics, Vifor Pharma, Novo Nordisk, Vertex Pharmaceuticals, NewBridge Pharmaceuticals and Pharmacosmos and research funding from Agios Pharmaceuticals and Pharmacosmos. E.V. reports consultancy and research funding from Agios, bluebird bio, Global Blood Therapeutics, Novartis and Pfizer. M.D.C. reports consultancy fees from Novartis, Bristol Myers Squibb (Celgene Corp), Vifor Pharma and Vertex Pharmaceuticals and research funding from Novartis, Bristol Myers Squibb (Celgene Corp), La Jolla Pharmaceutical Company, Roche, Protagonist Therapeutics and CRISPR Therapeutics. M.T. reports consultancy fees from Agios Pharmaceuticals, Beam Therapeutics and Novo Nordisk. D.H., R.D., S.F., M.A. and L.D.F. declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"45"}}